CLASS II ONGOING Device recall · Reported 2 Jul 2025 · FDA Enforcement Report

Caphosol Artificial Saliva (32 doses sachet box) recalled

Recordati Rare Diseases is recalling Caphosol Artificial Saliva (32 doses sachet box), distributed nationwide in the US. The recall was initiated on 11 Jun 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: 5060146293129. Lot Numbers: 001U002U, 001U002UA. Expiration 2026-10
Quantity recalled3,754 boxes (120,128 doses)

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2012-2025
FDA event ID
97007
Recalling firm
Recordati Rare Diseases, Bridgewater, NJ
Classification
Class II
Status
Ongoing
Recall initiated
11 Jun 2025
FDA classified
23 Jun 2025
Reported
2 Jul 2025
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Potency & Assay

Timeline

11 Jun 2025Recall initiated by company
23 Jun 2025Classified by FDA+12 days
2 Jul 2025Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Out of specification stability test result for the Caphosol B solution from process validation lots

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Caphosol Artificial Saliva (32 doses sachet box). 64 x 15 mL sachets aqueous solution (32 sachets Solution A Phosphate, 32 sachets Solution B Calcium)

Where it was distributed

Worldwide - US Nationwide distribution in the states of GA, OH, TN, TX, VA and the countries of Germany, France, Italy, Portugal, Spain, Sweden, United Kingdom.

Nationwide GeorgiaOhioTennesseeTexasVirginia

Questions about this recall

Why was it recalled?

Out of specification stability test result for the Caphosol B solution from process validation lots

Which lots are affected?

UDI-DI: 5060146293129. Lot Numbers: 001U002U, 001U002UA. Expiration 2026-10

Where was it sold?

Worldwide - US Nationwide distribution in the states of GA, OH, TN, TX, VA and the countries of Germany, France, Italy, Portugal, Spain, Sweden, United Kingdom.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other Other Medical Devices recalls

All 13,908